Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Grunberger

Showing results (1-10 of 108) with videos related to

Pageof 11
Sort By:
Current Diabetes Reports|March 16, 2017
Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?George Grunberger
Journal of Diabetes|March 16, 2013
Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013George Grunberger
Journal of Diabetes|March 13, 2020
Continuous glucose monitoring: Musing on our progress in memory of Dr Andrew Jay DrexlerGeorge Grunberger
European Journal of Clinical Pharmacology|September 2, 2014
Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trialsGeorge Grunberger
Diabetes Care|November 22, 2019
Fred W. Whitehouse, MD, MACP (1926-2019)George Grunberger
Expert Opinion on Pharmacotherapy|August 2, 2011
Quo vadis nateglinide? Ten-year perspectiveGeorge Grunberger
Postgraduate Medicine|June 11, 2013
Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptinGeorge Grunberger
Journal of Diabetes|March 5, 2013
Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QRGeorge Grunberger
Journal of Diabetes|June 15, 2011
Do we need a fasting lipid profile to assess cardiovascular risk?George Grunberger
Diabetes Care|September 25, 2014
Response to comment on Grunberger "insulin analogs-are they worth it? Yes!" Diabetes Care 2014;37:1767-1770 and Davidson "insulin analogs-is there a compelling case to use them? No!" Diabetes Care 2014;37:1771-1774George Grunberger
Pageof 11

Showing results (1-10 of 108) with videos related to

Sort By:
Pageof 11
Current Diabetes Reports|March 16, 2017
Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?George Grunberger
Journal of Diabetes|March 16, 2013
Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013George Grunberger
Journal of Diabetes|March 13, 2020
Continuous glucose monitoring: Musing on our progress in memory of Dr Andrew Jay DrexlerGeorge Grunberger
European Journal of Clinical Pharmacology|September 2, 2014
Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trialsGeorge Grunberger
Diabetes Care|November 22, 2019
Fred W. Whitehouse, MD, MACP (1926-2019)George Grunberger
Expert Opinion on Pharmacotherapy|August 2, 2011
Quo vadis nateglinide? Ten-year perspectiveGeorge Grunberger
Postgraduate Medicine|June 11, 2013
Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptinGeorge Grunberger
Journal of Diabetes|March 5, 2013
Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QRGeorge Grunberger
Journal of Diabetes|June 15, 2011
Do we need a fasting lipid profile to assess cardiovascular risk?George Grunberger
Diabetes Care|September 25, 2014
Response to comment on Grunberger "insulin analogs-are they worth it? Yes!" Diabetes Care 2014;37:1767-1770 and Davidson "insulin analogs-is there a compelling case to use them? No!" Diabetes Care 2014;37:1771-1774George Grunberger
Pageof 11